Advances in antibody-mediated immunity againstMycobacterium tuberculosis: implications for a novel vaccine strategy (Q35558612)

8 August 2017

1 reference

title

Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy (English)

1 reference

8 August 2017

Advances in antibody-mediated immunity againstMycobacterium tuberculosis: implications for a novel vaccine strategy (English)

1 reference

https://api.crossref.org/works/10.1016/S0928-8244(03)00172-X

Mycobacterium tuberculosis

21 March 2024

main subject

0 references

1 reference

https://api.crossref.org/works/10.1016/S0928-8244(03)00172-X

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0928-8244(03)00172-X

21 March 2024

author

Aharona Glatman-Freedman

series ordinal

1

object named as

Aharona Glatman-Freedman

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556990

21 March 2024

publication date

1 October 2003

1 reference

8 August 2017

24 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556990

full work available at URL

21 March 2024

published in

FEMS Immunology and Medical Microbiology

1 reference

8 August 2017

39

1 reference

8 August 2017

1

1 reference

8 August 2017

9-16

1 reference

The interplay of an immune substance with tuberculopolysaccharide and its antibody in tuberculosis.

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Serum therapy revisited: animal models of infection and development of passive antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

More is not necessarily better: prozone-like effects in passive immunization with IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Hypothesis: how licensed vaccines confer protective immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Antibodies highly effective in SCID mice during infection by the intracellular bacterium Ehrlichia chaffeensis are of picomolar affinity and exhibit preferential epitope and isotype utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Prospects for better tuberculosis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Internet resources for pediatric infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Vaccines against polysaccharide antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

The envelope layers of mycobacteria with reference to their pathogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

The capsule of Mycobacterium tuberculosis and its implications for pathogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Antibody formation to trehalose-6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Further study on neutralization of biochemical activity of cord factor by anti-cord factor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Heterogenous expression of the related MPB70 and MPB83 proteins distinguish various substrains of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Capsulate bacteria and the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Identification of a heparin-binding hemagglutinin present in mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Immune Mechanisms of Protection

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Local role for tumor necrosis factor alpha in the pulmonary inflammatory response to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Antibody-mediated protection against intracellular pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1-->3)-mannobiose moieties

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Synthesis and immunologic characterisation of Mycobacterium tuberculosis lipoarabinomannan specific oligosaccharide-protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

THE OCCURRENCE AND VIRULENCE OF PNEUMOCOCCI IN THE CIRCULATING BLOOD DURING LOBAR PNEUMONIA AND THE SUSCEPTIBILITY OF PNEUMOCOCCUS STRAINS TO UNIVALENT ANTIPNEUMOCOCCUS SERUM.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

EXPERIMENTAL INTRADERMAL PNEUMOCOCCUS INFECTION IN RABBITS

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

STUDIES ON EXPERIMENTAL PNEUMONIA : VII. TREATMENT OF EXPERIMENTAL PNEUMOCOCCUS TYPE I PNEUMONIA IN MONKEYS WITH TYPE I ANTIPNEUMOCOCCUS SERUM.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

CONCERNING A SERUM-THERAPY FOR EXPERIMENTAL INFECTION WITH DIPLOCOCCUS INTRACELLULARIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

PARAMENINGOCOCCUS AND ITS ANTISERUM.

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Roles of lipoarabinomannan in the pathogenesis of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0928-8244%2803%2900172-X

7 January 2021

Protective murine monoclonal antibodies to Cryptococcus neoformans

series ordinal

10

1 reference

https://api.crossref.org/works/10.1016/S0928-8244(03)00172-X

An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis

21 March 2024

series ordinal

72

1 reference

https://api.crossref.org/works/10.1016/S0928-8244(03)00172-X

21 March 2024

Identifiers

1 reference

8 August 2017

1 reference